SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid–base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid–base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes
Authors
Keywords
-
Journal
CLINICAL SCIENCE
Volume 134, Issue 23, Pages 3107-3118
Publisher
Portland Press Ltd.
Online
2020-11-18
DOI
10.1042/cs20201274
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The association between serum chloride levels and chronic kidney disease progression: a cohort study
- (2020) Minesh Khatri et al. BMC Nephrology
- SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition
- (2020) Issei Tomita et al. Cell Metabolism
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- 250-OR: Beta-Cell Rest Induced by Dapagliflozin Improves ß-Cell Secretory Capacity in Type 2 Diabetes Patients: A Randomized Controlled Trial vs. Gliclazide
- (2019) ERIK J.M. VAN BOMMEL et al. DIABETES
- The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
- (2019) Erik J.M. van Bommel et al. KIDNEY INTERNATIONAL
- Role of Citrate in Pathophysiology and Medical Management of Bone Diseases
- (2019) Donatella Granchi et al. Nutrients
- Sodium–glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice
- (2018) Shinji Tanaka et al. KIDNEY INTERNATIONAL
- Urine tricarboxylic acid (TCA) cycle metabolites predict progressive chronic kidney disease in type 2 diabetes
- (2018) Jian-Jun Liu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis
- (2018) Maarten A. de Jong et al. Clinical Journal of the American Society of Nephrology
- Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
- (2018) Julio Rosenstock et al. DIABETES CARE
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart FailureClinical Perspective
- (2016) Jozine M. ter Maaten et al. Circulation-Heart Failure
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials
- (2016) Huilin Tang et al. DIABETOLOGIA
- Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney
- (2016) Biff F. Palmer et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Hypomagnesemia in Type 2 Diabetes: A Vicious Circle?
- (2015) Lisanne M.M. Gommers et al. DIABETES
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Possible adverse effects of SGLT2 inhibitors on bone
- (2015) Simeon I Taylor et al. Lancet Diabetes & Endocrinology
- Renal Control of Calcium, Phosphate, and Magnesium Homeostasis
- (2014) J. Blaine et al. Clinical Journal of the American Society of Nephrology
- Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)
- (2014) Matthew R. Weir et al. CURRENT MEDICAL RESEARCH AND OPINION
- Hyperosmolar Hyperglycemic State: A Historic Review of the Clinical Presentation, Diagnosis, and Treatment
- (2014) Francisco J. Pasquel et al. DIABETES CARE
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
- (2012) Ö. Ljunggren et al. DIABETES OBESITY & METABOLISM
- Loss of insulin-induced activation of TRPM6 magnesium channels results in impaired glucose tolerance during pregnancy
- (2012) A. V. Nair et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started